Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02893917CT.gov Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02532114CT.gov Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT02048150CT.gov Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer | — | Completed | — | — | — |
NCT02184533CT.gov Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | — | Completed | — | — | — |
NCT01325311CT.gov Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | — | Completed | — | — | — |
NCT01120236CT.gov Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT01228084CT.gov Sulforaphane in Treating Patients With Recurrent Prostate Cancer | — | Completed | — | — | — |
NCT00527124CT.gov Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Terminated | — | — | — |
NCT00450229CT.gov Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer | — | Completed | — | — | — |
NCT00536991CT.gov Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
Show 3 more trialsShow fewer
NCT00096499CT.gov SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | — | Completed | — | — | — |
NCT00170157CT.gov Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00502164CT.gov Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | National Cancer Institute (NCI) | P2 | BB · 68 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cediranib in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cediranib-prostate-adenocarcinoma-28538
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →